'New drugs soon for malaria, diabetes'

'The "candidate drugs" for malaria, osteoporosis and diabetes were currently undergoing clinical trials'

April 12, 2015 02:51 am | Updated 03:31 am IST - NEW DELHI:

The “candidate drugs” for malaria, osteoporosis and diabetes were currently undergoing clinical trials. Photo: V.V.Krishnan

The “candidate drugs” for malaria, osteoporosis and diabetes were currently undergoing clinical trials. Photo: V.V.Krishnan

The Indian pharmaceutical sector would soon be showcasing ‘candidate drugs’ for malaria, osteoporosis and diabetes, Union Minister for Science and Technology and Earth Sciences Harsh Vardhan said on Saturday.

With further R&D, important breakthroughs could be on the horizon for these diseases, he said following a visit to the Central Drug Research Institute (CDRI), Lucknow, a wing of the Council of Scientific and Industrial Research (CSIR).

Addressing scientists, he said Prime Minister Narendra Modi was committed to making India one of the world’s leading destinations for end-to-end drug discovery and innovation by 2020.

“I am confident that the drug laboratories under the CSIR are capable of backing up the Swasth Swachh Bharat Mission. Our scientists are focussing on both infectious and lifestyle diseases. We are developing next generation drugs, biologics, biosimilars, gene therapeutics, stem cell therapeutics, personalised medicine and multifunctional nanomedicine,” said Dr. Vardhan.

Indian R&D efforts in government laboratories like CSIR-CDRI, CSIR-Indian Institute of Chemical Technology (CSIR-IICT, Hyderabad) and CSIR-Indian Institute of Chemical Biology (CSIR-IICB, Kolkata) have a track record in making drugs for kala azar, filaria, leprosy and tuberculosis available at affordable rates to the common man, he said.

Under clinical trial

The “candidate drugs” for malaria, osteoporosis and diabetes were currently undergoing clinical trials, he said, adding that the CSIR-CDRI were simultaneously carrying out Investigational New Drug (IND) studies on lead molecules for fracture-healing, cancers, thrombosis, malaria and hyperglycemia. “Strengthening of the R&D ecosystem is the priority,” he added.

He also said people were expecting CSIR laboratories to produce therapeutic and preventive measures for re-emerged infectious diseases.

0 / 0
Sign in to unlock member-only benefits!
  • Access 10 free stories every month
  • Save stories to read later
  • Access to comment on every story
  • Sign-up/manage your newsletter subscriptions with a single click
  • Get notified by email for early access to discounts & offers on our products
Sign in

Comments

Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.

We have migrated to a new commenting platform. If you are already a registered user of The Hindu and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.